Skip to main content

Table 1 Baseline characteristics at admission of the entire group, and comparisons between survivors and non-survivors.

From: Lung Function and Organ Dysfunctions in 178 Patients Requiring Mechanical Ventilation During The 2009 Influenza A (H1N1) Pandemic

  All (n= 178) Survivors (n= 93; 52%) Non-survivors (n= 85; 48%) P-value
Age 44 ± 15 45 ± 16 43 ± 15 0.36
Male gender 98 (55%) 49 (53%) 49 (58%) 0.44
APACHE II 18 ± 7 17 ± 6 20 ± 7 0.001
SOFA 4 (5 to 8) 3 (5 to 7) 6 (4 to 8) 0.000
Days of symptoms 6.7 ± 4.3 5.8 ± 3 7.5 ± 5 0.014
BMI 28 ± 8 28 ± 6 29 ± 10 0.32
Obesity1 46 (26%) 17 (18%) 29 (34%) 0.016
COPD 28 (16%) 16 (17%) 12 (14%) 0.57
Asthma 10 (6%) 6 (6%) 4 (5%) 0.61
Other respiratory disease 5 (3%) 1 (1%) 4 (5%) 0.14
Chronic heart failure 10 (6%) 3 (3%) 7 (8%) 0.15
Other cardiac disease 8 (4%) 6 (6%) 2 (2%) 0.19
Ethilism/alcoholism 12 (7%) 8 (9%) 4 (5%) 0.30
Chronic hepatic disease 7 (4%) 1 (1%) 6 (7%) 0.04
Diabetes 16 (9%) 5 (5%) 11 (13%) 0.08
Chronic renal failure 13 (7%) 5 (5%) 8 (9%) 0.31
Immunosupression2 29 (16%) 10(11%) 19(22%) 0.04
Pregnancy 16 (9%) 7 (8%) 9 (11%) 0.47
Previous seasonal influenza vaccination 4 (4%) 2 (2%) 2 (2%) 0.93
Confirmed cases by RT-PCR testing 95 (53%) 49 (53%) 46 (54%) 0.85
Oseltamivir use3 174 (98%) 91 (98%) 82 (67%) 0.58
Corticosteroid use4 75 (42%) 40% 45% 0.51
Length of MV 10 (6 to 17) 11 (6 to 19) 10 (4 to 16) 0.05
LOSICU 12 (7 to 19) 14 (10 to 22) 10 (4 to 16) < 0.001
LOSHOSPITAL 16 (10 to 23) 21 (14 to 38) 11 (6 to 18) < 0.001
  1. BMI, body mass index; ICU, intensive care unit; LOSICU, length of stay at the ICU, in days; LOSHOSPITAL, length of stay at the hospital, in days; MV, mechanical ventilation
  2. 1 Obesity was defined as a BMI > 30
  3. 2 Includes neoplasia, infection by human immunodeficiency virus, and autoimmune disease.
  4. 3 For corresponding doses, see reference 14.
  5. 4 Corticosteroids were prescribed in 36% of patients for septic shock as 300 mg/day of hydrocortisone. Ten percent received metilprednisolone for persistent ARDS; 3% for other reasons, and 2% were pregnant patients receiving antenatal dexametasone to accelerate maturation of fetal lungs.